Thermo Fisher Scientific Inc
TMO#74 of 134 by buybacksNYSE · Healthcare · Diagnostics & Research · USA
thermofisher.comBuybacks · FY2025$3.00Blatest fiscal year
Buyback yield1.2%repurchases ÷ market cap
Dividends · FY2025$636Mdividend yield 0.3%
Shareholder yield1.5%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−6.8%371M shares (2026)
Buybacks ÷ free cash flow48%payout incl. dividends 58%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $3.00B | $636M | $6.29B |
| FY2024Dec 2024 | $4.00B | $583M | $7.27B |
| FY2023Dec 2023 | $3.00B | $523M | $6.93B |
| FY2022Dec 2022 | $3.00B | $455M | $6.91B |
| FY2021Dec 2021 | $2.00B | $395M | $7.02B |
| FY2020Dec 2020 | $1.50B | $337M | $6.82B |
| FY2019Dec 2019 | $1.50B | $297M | $4.05B |
Repurchases in FY2025 were −25.0% versus the prior year.
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infe…
- Market cap
- $243B
- P/E (trailing)
- 35.1×
- Fiscal year end
- December
- ISIN
- US8835561023
- Reporting currency
- USD
- Data updated
- Oct 10, 2026